Related references
Note: Only part of the references are listed.Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma The METGastric Randomized Clinical Trial
Manish A. Shah et al.
JAMA ONCOLOGY (2017)
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
M. Zhu et al.
BRITISH JOURNAL OF CANCER (2015)
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Y. Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
c-Met targeting in advanced gastric cancer: An open challenge
Luigi Marano et al.
CANCER LETTERS (2015)
Rilotumumab Exposure-Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
Sameer Doshi et al.
CLINICAL CANCER RESEARCH (2015)
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
Roland Morley et al.
PLOS ONE (2015)
High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis
HeLi Gao et al.
TUMOR BIOLOGY (2015)
The clinical and functional significance of c-Met in breast cancer: a review
Colan M. Ho-Yen et al.
BREAST CANCER RESEARCH (2015)
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
Yilong Zhang et al.
BIOMEDICINES (2015)
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Ravi Salgia et al.
CLINICAL CANCER RESEARCH (2014)
Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients
Min Zhu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson et al.
LANCET ONCOLOGY (2014)
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
Kensei Yamaguchi et al.
GASTRIC CANCER (2013)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
Francesco Graziano et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Michael S. Gordon et al.
CLINICAL CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings
Beatrice S. Knudsen et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Katsuhiro Okuda et al.
CANCER SCIENCE (2008)
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts
H. Toni Jun et al.
CLINICAL CANCER RESEARCH (2007)
Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer
Ainhoa Viteri et al.
ACTA ONCOLOGICA (2007)
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer
TW Kim et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
